New York Institute of Technology College of Osteopathic Medicine Kent, CT
Ifeoma P. Kwentoh, MD1, Ikponmwosa Jude. Ogieuhi, MD, PhD, BSc2, Victor Ajekiigbe, MD3, Farirai Melania Marwizi, MD4, Bright Nwatamole, MBBS5, Damilola Ifeoluwa Fatokun, MD3, Chidera Stanley Anthony, MD6, Olanrewaju Adeniran, MD7, Adedeji Adenusi, MD, MPH8, Eunice Aregbesola, MD9 1New York Institute of Technology College of Osteopathic Medicine, Kent, CT; 2Siberian State Medical University, Tomsk, Tomsk, Russia; 3LAUTECH Teaching Hospital, Ogbomosho-Ilorin Road, Ogbomoso, Ogbomosho, Oyo, Nigeria; 4St John's Episcopal 327 Beach 19th St, Far Rockaway, NY 11691, Queens, NY; 5Vassar Brothers Medical Center - Nuvance Health, Poughkeepsie, NY; 6Faculty of Clinical Sciences, University of Calabar Nigeria, Calabar, Cross River, Nigeria; 7West Virginia University Morgantown, Morgantown, WV; 8One Brooklyn Health-Interfaith Medical Center, Brooklyn, NY; 9University of Missouri, Columbia, USA, Columbia, MO Introduction: Fecal microbiota transplantation (FMT) is a promising approach for managing inflammatory bowel diseases (IBD). This narrative review explores and discusses fourteen studies from clinical trials conducted between 2015 and 2024 with 326 participants. Methods: A thorough literature search was done. The focus was to find clinical trials and studies on fecal microbiota transplantation (FMT) for treating Inflammatory Bowel Diseases (IBD), such as ulcerative colitis and Crohn’s disease. The databases PubMed, Science Direct, EMBASE, Cochrane, Web of Science, and Google Scholar were used, spanning publications from January 2015 to September 2024. Key search terms like "fecal microbiota transplantation," "IBD," "FMT," "inflammatory bowel disease," "ulcerative colitis," and "Crohn’s disease" were utilized, combined using Boolean operators (AND, OR) for effective results. Filters helped limit the search to human trials, especially clinical and randomized controlled trials. Beyond the database search, references within relevant articles were manually checked to locate other qualifying studies—figure 1. Results: Dysregulation of the microbiome plays a key role in the cause of inflammatory bowel disease (IBD). Fecal microbiota transplantation (FMT) has shown several promising treatment options in patients with IBD (Ulcerative Colitis and Crohn’s disease) that are superior to standard therapy with the ultimate goal of correcting the underlying dysbiosis. We included 14 studies (Table 1) with 326 total participants conducted between 2015 and 2024. Study designs varied from prospective single-center trials to double-blinded and randomized clinical trials (RCT). Participants had a wide age range. Donor samples were mostly healthy unrelated patients. FMT administration routes ranged from nasogastric access with minimally invasive techniques to invasive colonoscopy and endoscopy procedures requiring downtime and anesthesia. Discussion: The general safety profile of the procedure was favorable in most of the studies, with mild adverse effects observed. Therapy success depends on several factors, including donor microbiome, baseline disease severity, and administration frequency. The efficacy and safety of fecal microbiota transplantation in managing IBD prove its utility, especially as an alternative to conventional treatment regimens. However, adequately powered, multicenter randomized clinical trials are needed to substantiate the extent to which these factors influence the clinical outcomes of FMT
Figure: PRISMA 2020 flow diagram for new systematic reviews
Figure: Overview of Clinical Studies
Disclosures: Ifeoma Kwentoh indicated no relevant financial relationships. Ikponmwosa Ogieuhi indicated no relevant financial relationships. Victor Ajekiigbe indicated no relevant financial relationships. Farirai Melania Marwizi indicated no relevant financial relationships. Bright Nwatamole indicated no relevant financial relationships. Damilola Ifeoluwa Fatokun indicated no relevant financial relationships. Chidera Stanley Anthony indicated no relevant financial relationships. Olanrewaju Adeniran indicated no relevant financial relationships. Adedeji Adenusi indicated no relevant financial relationships. Eunice Aregbesola indicated no relevant financial relationships.
Ifeoma P. Kwentoh, MD1, Ikponmwosa Jude. Ogieuhi, MD, PhD, BSc2, Victor Ajekiigbe, MD3, Farirai Melania Marwizi, MD4, Bright Nwatamole, MBBS5, Damilola Ifeoluwa Fatokun, MD3, Chidera Stanley Anthony, MD6, Olanrewaju Adeniran, MD7, Adedeji Adenusi, MD, MPH8, Eunice Aregbesola, MD9. P5388 - Management of Inflammatory Bowel Diseases and Role of Fecal Microbiota Transplantation: A Narrative Review of Clinical Trials, ACG 2025 Annual Scientific Meeting Abstracts. Phoenix, AZ: American College of Gastroenterology.
